Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain.
De Pas
T
T
Department of Medical Oncology, European Institute of Oncology, Milan, Italy. tommaso.de-pas@ieo.it
Sbanotto
A
A
Catania
C
C
Banfi
M G
MG
Curigliano
G
G
Nolè
F
F
Fazio
N
N
Formica
V
V
Veronesi
G
G
de Braud
F
F
D000208:Acute Disease; D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D000284:Administration, Oral; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D013274:Stomach Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
D014747:Vinblastine; D000077235:Vinorelbine